Alkahest competitors

Mr. Sherman joined Chimerix in 2019 as Chief Executive Officer. Before joining the Company, he served as Chief Executive Officer of Endocyte and led it from a $200 million market capitalization to its $2.1 billion acquisition by Novartis in 2018. Mr. Sherman repositioned the company by re-prioritizing the pipeline, acquiring an external asset, and aggressively executing a phase 3 regulatory and clinical strategy. He joined the company in 2006 and as Chief Financial Officer and Chief Operating Officer and was instrumental in Endocyte’s IPO and four subsequent financings. Prior to joining Endocyte, Mr. Sherman served in various executive roles, including as vice president of finance and strategic planning for Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation. Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth, graduating as a Tuck Scholar. Mr. Sherman currently serves on the Board of Biospecifics Technologies, Inc, and as Chairman of the Board of Trustees for the Children’s Museum of Indianapolis. He also served on the Board of Directors at Mead Johnson Nutrition until the company’s acquisition by Reckitt Benckiser.

As a senior executive with 20+ years of sell- and buy- side business and corporate development experience, my career encompasses roles in therapeutics, biotech, genomics, medical devices, and pharmacy benefits. During my tenure at Pfizer, I completed more than 2 dozen acquisition, co-development, and licensing deals ranging from $300M to $7B. Later at Foundation Medicine, I led the $1B sale of their genomics testing to Roche, and earlier played a leadership role in Medco’s $29B sale to Express Scripts. I have worked extensively within R&D environments and launched 3 $1B+ therapeutic products in the hypertension and antibiotics categories. Additionally, I have been the CEO of early stage start-ups, building the funding, commercialization, and exit strategy for therapeutics companies in the CNS and autoimmune disease space.Currently, as CEO of Cognition Therapeutics, I am driving Series C fundraising effort. With multiple phase 2 clinical trials well under way for the Alzheimer’s research and more than a hundred million dollars in dedicated funding, I am repositioning the company to broaden the focus on our science and other CNS clinical conditions. I am pleased to lead a company dedicated to halting neurological disease processes and restoring and preserving the building blocks of brain health and function and look forward to sharing our progress here.

Dr. Rienhoff is a physician, entrepreneur and founder of several biotech and presently serves as CEO of Imago BioSciences. Dr. Rienhoff was the founder and CEO of FerroKin Biosciences, a development stage company that was acquired by Shire in for $325 million in 2012. He has more than 20 years experience as both a venture investor and entrepreneur in the life science sector. He was a partner at New Enterprise Associates and later, a director of Abingworth Management Ltd., running their US operation. Dr. Rienhoff is an Adjunct Scientist at the Children's Hospital Oakland Research Institute. He received his M.D. from the Johns Hopkins University School of Medicine and his B.A. from Williams College.

Responsible for the business operations of AlderRecent Accomplishment: Raised two follow-ons in 2015 Jan 2015 raised $190.7MJune 2015 raised: $ 215.9MTotal 2015: $406.6MSuccessful IPO, May 7th 2014 raised $80M Nasdaq: ALDR Since founding Alder in 2004 we have• Raised almost $500M in the public markets since going public in 2014• Raised over $105M in four rounds of VC financings, major investors include Sevin Rosen funds, Five Corners (Ventures West ), HIG Ventures, TPG Biotech, Delphi Ventures, and Novo Ventures• Brought in $134M in revenue from collaborations and partnersIncludes $1.35B BMS Collaboration for Clazakizumabhttp://news.bms.com/press-release/rd-news/bristol-myers-squibb-and-alder-biopharmaceuticals-enter-global-agreement-rheumManagement Responsibilities include: Corporate Strategy Commercial Department Legal Department Business Development Department Finance Department Human Resources Alliance Management Facilities Information Technology